Merck reported robust third-quarter results with a 15% year-over-year revenue increase, driven primarily by the strong performance of KEYTRUDA. The raised full-year guidance and positive pipeline developments outweigh concerns about upcoming pricing pressures, suggesting investor confidence remains solid in the short term.

[1]